Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, et al.
The Lancet Microbe (2021) Vol. 2, Iss. 7, pp. e283-e284
Open Access | Times Cited: 414

Showing 1-25 of 414 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
Otávio T. Ranzani, Matt D. T. Hitchings, Murilo Dorión, et al.
BMJ (2021), pp. n2015-n2015
Open Access | Times Cited: 278
SARS-CoV-2 Variants of Concern
Jun Yong Choi, Davey M. Smith
Yonsei Medical Journal (2021) Vol. 62, Iss. 11, pp. 961-961
Open Access | Times Cited: 274
Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
Chee Wah Tan, Wanni Chia, Barnaby Edward Young, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1401-1406
Open Access | Times Cited: 203
Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2
Haibo Wu, Na Xing, Kaiwen Meng, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 12, pp. 1788-1801.e6
Open Access | Times Cited: 191
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 174
Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe
Vikram Thakur, Shivam Bhola, Pryanka Thakur, et al.
Infection (2021) Vol. 50, Iss. 2, pp. 309-325
Open Access | Times Cited: 167
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
Matt D. T. Hitchings, Otávio T. Ranzani, Mario Torres, et al.
The Lancet Regional Health - Americas (2021) Vol. 1, pp. 100025-100025
Open Access | Times Cited: 160
The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation
Maaran Michael Rajah, Annie Bernier, Julian Buchrieser, et al.
Journal of Molecular Biology (2021) Vol. 434, Iss. 6, pp. 167280-167280
Open Access | Times Cited: 153
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines
Suresh Thakur, Shalitha Sasi, Sindhu Gopinathan Pillai, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 133
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 118
SARS‐CoV‐2 variants and vulnerability at the global level
Vivek P. Chavda, Aayushi Patel, Darsh D. Vaghasiya
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2986-3005
Open Access | Times Cited: 108
Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 107
Nanotechnology-based strategies against SARS-CoV-2 variants
Xiangang Huang, Edo Kon, Xuexiang Han, et al.
Nature Nanotechnology (2022) Vol. 17, Iss. 10, pp. 1027-1037
Open Access | Times Cited: 102
Reinfection in patients with COVID-19: a systematic review
Xiangying Ren, Jie Zhou, Jing Guo, et al.
Global Health Research and Policy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 90
Emerging Vaccine-Breakthrough SARS-CoV-2 Variants
Rui Wang, Jiahui Chen, Yuta Hozumi, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 3, pp. 546-556
Open Access | Times Cited: 73
Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection
Chrispin Chaguza, Anne M. Hahn, Mary E. Petrone, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 2, pp. 100943-100943
Open Access | Times Cited: 73
SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy
Ziwei Yang, Yang Han, Shilei Ding, et al.
mBio (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
Immunity to SARS-CoV-2 up to 15 months after infection
Harold Marcotte, Antonio Piralla, Fanglei Zuo, et al.
iScience (2022) Vol. 25, Iss. 2, pp. 103743-103743
Open Access | Times Cited: 68
The success of SARS-CoV-2 vaccines and challenges ahead
Kanta Subbarao
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1111-1123
Open Access | Times Cited: 87
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions
Wajihul Hasan Khan, Zohra Hashmi, Aditya Goel, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 85
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma
Jiejie Geng, Liang Chen, Yufeng Yuan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 84
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
Weina Sun, Yonghong Liu, Fatima Amanat, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 84
E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil
Patrícia Aline Gröhs Ferrareze, Vinícius Bonetti Franceschi, Amanda de Menezes Mayer, et al.
Infection Genetics and Evolution (2021) Vol. 93, pp. 104941-104941
Open Access | Times Cited: 74
Page 1 - Next Page

Scroll to top